Human Growth Hormone

Human Growth Hormone

• Home
• What is HGH?
• Search
• Syndicate
• More Health

See Also

Human Growth Hormone > Nutropin > California

Please select a HGH news story from the list below:

• Business Wire - Genentech Reports 28 Percent Increase in Product Sales for Second Quarter; 21 Percent Increase in Pro Forma Earnings Per Share
• Biotech Equipment Update - FDA APPROVES NUTROPIN AQ PEN FOR DELIVERY OF GROWTH HORMONE.(Genetech Inc.)
• Business Wire - FDA Approves Nutropin AQ Pen for Delivery of Nutropin AQ Recombinant Growth Hormone
• Business Wire - Schwarz Pharma's Rights to Growth Hormone Products Reacquired by Genentech; Schwarz Pharma to Focus on Central Nervous System and Urology
• Business Wire - Genentech Reports 30 Percent Increase in Net Income and 28 Percent Increase in Earnings Per Share for 2000
• Business Wire - Genentech and Alkermes to Expand Clinical Development of Nutropin Depot
• Business Wire - Genentech Reports 15 Percent Increase in Product Sales for Second Quarter; Earnings Driven by Sales of Rituxan and Herceptin
• Biotech Financial Reports - GENENTECH REPORTS 21% INCREASE IN 1ST QTR PRODUCT SALES.(Brief Article)(Statistical Data Included)
• Business Wire - Genentech Reports 21 Percent Increase in Product Sales for First Quarter; 27 Percent Increase in Earnings Per Share, Exclusive of Impact of Redemption
• Business Wire - GENENTECH REPORTS 1999 YEAR-END RESULTS; 1999 Revenues Driven by 45 Percent Increase in Product Sales

Business Wire - Genentech Reports 28 Percent Increase in Product Sales for Second Quarter; 21 Percent Increase in Pro Forma Earnings Per Share

July 10, 2002 -- Business Editors/Health & Medical Writers Genentech, Inc. (NYSE:DNA) today announced second quarter pro forma financial results of 23 cents per...

• Business Wire - Genentech Reports 28 Percent Increase in Product Sales for Second Quarter; 21 Percent Increase in Pro Forma Earnings Per Share

Biotech Equipment Update - FDA APPROVES NUTROPIN AQ PEN FOR DELIVERY OF GROWTH HORMONE.(Genetech Inc.)

June 1, 2002 -- Genentech, Inc. (NYSE:DNA), South San Francisco, has announced that the Nutropin AQ Pen(TM) has received clearance from the FDA. The Nutropin AQ...

• Biotech Equipment Update - FDA APPROVES NUTROPIN AQ PEN FOR DELIVERY OF GROWTH HORMONE.(Genetech Inc.)

Business Wire - FDA Approves Nutropin AQ Pen for Delivery of Nutropin AQ Recombinant Growth Hormone

April 23, 2002 -- Business Editors/Health & Medical Writers SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--April 23, 2002 Latest Innovation from Genentech's...

• Business Wire - FDA Approves Nutropin AQ Pen for Delivery of Nutropin AQ Recombinant Growth Hormone

Business Wire - Schwarz Pharma's Rights to Growth Hormone Products Reacquired by Genentech; Schwarz Pharma to Focus on Central Nervous System and Urology

June 8, 2001 -- Business Editors SOUTH SAN FRANCISCO, Calif. & MONHEIM, Germany--(BUSINESS WIRE)-- June 7, 2001 Schwarz Pharma AG and Genentech, Inc. announced...

• Business Wire - Schwarz Pharma's Rights to Growth Hormone Products Reacquired by Genentech; Schwarz Pharma to Focus on Central Nervous System and Urology

Business Wire - Genentech Reports 30 Percent Increase in Net Income and 28 Percent Increase in Earnings Per Share for 2000

January 18, 2001 -- Business Editors/Medical & Health Writers SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jan. 18, 2001 2000 Performance Driven by 23 Percent...

• Business Wire - Genentech Reports 30 Percent Increase in Net Income and 28 Percent Increase in Earnings Per Share for 2000

Business Wire - Genentech and Alkermes to Expand Clinical Development of Nutropin Depot

January 8, 2001 -- Business Editors/Medical Writers SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass.--(BW HealthWire)-- Jan. 8, 2001 Genentech, Inc. (NYSE:DNA) and...

• Business Wire - Genentech and Alkermes to Expand Clinical Development of Nutropin Depot

Business Wire - Genentech Reports 15 Percent Increase in Product Sales for Second Quarter; Earnings Driven by Sales of Rituxan and Herceptin

July 17, 2000 -- Business Editors SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--July 17, 2000 Genentech, Inc. (NYSE:DNA) today announced a 15 percent increase in...

• Business Wire - Genentech Reports 15 Percent Increase in Product Sales for Second Quarter; Earnings Driven by Sales of Rituxan and Herceptin

Biotech Financial Reports - GENENTECH REPORTS 21% INCREASE IN 1ST QTR PRODUCT SALES.(Brief Article)(Statistical Data Included)

May 1, 2000 -- Genentech, Inc. (NYSE:DNA), South San Francisco, has announced a 21 percent increase in product sales and a 27 percent increase in earnings per...

• Biotech Financial Reports - GENENTECH REPORTS 21% INCREASE IN 1ST QTR PRODUCT SALES.(Brief Article)(Statistical Data Included)

Business Wire - Genentech Reports 21 Percent Increase in Product Sales for First Quarter; 27 Percent Increase in Earnings Per Share, Exclusive of Impact of Redemption

April 12, 2000 -- Business Editors and Health/Medical Writers SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--April 12, 2000 Genentech, Inc. (NYSE:DNA) today...

• Business Wire - Genentech Reports 21 Percent Increase in Product Sales for First Quarter; 27 Percent Increase in Earnings Per Share, Exclusive of Impact of Redemption

Business Wire - GENENTECH REPORTS 1999 YEAR-END RESULTS; 1999 Revenues Driven by 45 Percent Increase in Product Sales

January 20, 2000 -- Business Editors &Biotech Writers SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jan. 20, 2000 Genentech, Inc. (NYSE: DNA) announced today the...

• Business Wire - GENENTECH REPORTS 1999 YEAR-END RESULTS; 1999 Revenues Driven by 45 Percent Increase in Product Sales

Cities

cambridge editors south san francisco medical writers south san francisco monheim south san francisco

Province/States

california massachusetts

Country

germany

Company

2001 schwarz pharma ag

Product

nutropin aq pen